Search
Bifonazole
go.drugbank.com/drugs/DB04794ApprovedBifonazole is an azole antifungal drug.
Categories: Antifungals for Topical Use, Antifungals for Dermatological UseTofacitinib
go.drugbank.com/drugs/DB08895ApprovedInvestigationalTofacitinib is marketed under the brand name Xeljanz by Pfizer. … It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate.
Sulfapyridine
go.drugbank.com/drugs/DB00891ApprovedWithdrawnAntibacterial, potentially toxic, and previously used to treat certain skin diseases. No longer prescribed.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseEstradiol benzoate
go.drugbank.com/drugs/DB13953ApprovedVet approvedWithdrawnEstradiol benzoate is not currently available in Canada or the US. … First-pass metabolism by the gut and the liver quickly degrades the estradiol molecule before it gets a chance to enter systemic circulation and exert its estrogenic effects [A12102].
Categories: Hormonal Contraceptives for Systemic UseVirginiamycin
go.drugbank.com/drugs/DB11476ExperimentalVet approvedAccording to a USDA study, antibiotics can save as much as 30% in feed costs among young swine.
Categories: Antibiotics for Topical UseObecabtagene autoleucel
go.drugbank.com/drugs/DB17362ApprovedInvestigational[A265040,A265045] It works by targeting B-cell-specific CD19 surface markers present on malignant B cells. … [A265050] On November 8, 2024, obecabtagene autoleucel was approved by the FDA for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Synonyms: AUTOLOGOUS CD4+ AND CD8+ T CELLS, ENRICHED FROM PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS) OBTAINED BY APHERESIS TRANSDUCED EX VIVO WITH A NON-REPLICATING, SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING19-Nor-5-androstenedione
go.drugbank.com/drugs/DB01443ExperimentalIllicitIt is regulated in the United States as a schedule III controlled substance, and prohibited by the World Anti-Doping Agency for use in competitive sports.
Influenza A virus A/Darwin/6/2021 (H3N2) recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB16922ApprovedRecombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen
Influenza B virus B/Austria/1359417/2021 BVR-26 antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB16925ApprovedWithdrawnRecombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen
Influenza A virus A/West Virginia/30/2022 (H1N1) Recombinant Hemagglutinin Antigen
go.drugbank.com/drugs/DB17995ApprovedWithdrawnRecombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen